Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [8][29]. Core Insights - The industry is experiencing a return to normal growth, with a notable performance in chemical pharmaceuticals, while the overall revenue growth for 2024 is projected to decline by 0.6% year-on-year, marking the first decline in recent years [12][14]. - The report highlights a significant disparity among sectors, with chemical pharmaceuticals showing a remarkable net profit growth of 97.7%, while biological products face substantial short-term performance pressure [17][18]. - The current low allocation and valuation levels present a high cost-performance ratio for investments in the pharmaceutical sector, suggesting it is an excellent time to allocate resources [19][28]. Summary by Sections 1. Innovation in the Pharmaceutical Chain - The report notes that the impact of national procurement and anti-corruption measures is gradually diminishing, leading to a normal release of rigid demand in hospitals [11]. - The overall revenue growth for the industry in 2024 is projected at -0.6%, with net profit and non-recurring net profit declining by 8.1% and 5.9% respectively [12][13]. 2. Investment Recommendations - The report suggests focusing on the innovation drug supply chain (Biotech + CXO + upstream) and certain overseas medical devices, recommending companies such as Aosaikang, Yifang Bio, and WuXi AppTec for investment [29]. - For in-hospital products (traditional Chinese medicine, chemical pharmaceuticals, and medical devices), companies like Hengrui Medicine and Mindray Medical are highlighted as having more certain growth prospects [29]. 3. Market Positioning - The report indicates that the allocation of public fund products in pharmaceutical stocks has decreased from 11.2% in Q1 2024 to 8.7% in Q4 2024, with a slight recovery to 9.1% by Q1 2025 [19][21]. - The pharmaceutical sector's price-to-earnings ratio is at a 10-year low, suggesting potential for growth as innovative products continue to emerge [22][24].

Market Performance - On May 6, the Shanghai Composite Index rose by 1.13%, the Shenzhen Component Index increased by 1.84%, and the ChiNext Index gained 1.97% [2] - A total of 59 stocks appeared on the "Dragon and Tiger List" due to significant price movements, with the highest net inflow of funds recorded for Yanshan Technology (002195.SZ) at 214 million yuan [2][3] Stock Highlights - Yanshan Technology saw a net purchase of 214 million yuan, accounting for 8.26% of the total trading volume, and closed with a 10.1% increase and a turnover rate of 8.41% [3][5] - The stock with the highest net outflow was Changshan Beiming (000158.SZ), which experienced a net sell of 148 million yuan, representing 2.37% of the total trading volume, and closed up by 10.02% with a turnover rate of 16.36% [3][6] Institutional Activity - Institutions were active in 27 stocks on the Dragon and Tiger List, with a total net purchase of 428 million yuan, buying 11 stocks and selling 16 [7] - The stock with the highest institutional net purchase was Qingdao Kingking (002094.SZ), which closed up by 9.97% and had a turnover rate of 19.6% [7] Northbound Capital - Northbound funds participated in 11 stocks on the Dragon and Tiger List, with a total net purchase of 216 million yuan, including a net buy of 83.6 million yuan for Yanshan Technology [12] - The stock with the highest net sell from northbound funds was Changshan Beiming, with a net sell of 29.4 million yuan [12] Summary of Key Stocks - Yanshan Technology: Net buy of 409.7 million yuan from institutions and 836.2 million yuan from northbound funds, with a total net buy of 1.2458 billion yuan [16] - Changshan Beiming: Net sell of 39.37 million yuan from institutions and 29.38 million yuan from northbound funds, totaling a net sell of 68.75 million yuan [16]

奥赛康今日下跌5.80%，全天换手率1.45%，成交额2.40亿元，振幅6.82%。龙虎榜数据显示，机构净卖 出1773.60万元，深股通净买入644.63万元，营业部席位合计净卖出1043.33万元。 深交所公开信息显示，当日该股因日跌幅偏离值达-8.05%上榜，机构专用席位净卖出1773.60万元，深 股通净买入644.63万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.18亿元，其中，买入成交额为4795.57 万元，卖出成交额为6967.88万元，合计净卖出2172.31万元。 具体来看，今日上榜的营业部中，共有7家机构专用席位现身，即买二、买三、买四、买五、卖二、卖 四、卖五，合计买入金额2274.61万元，卖出金额4048.22万元，合计净卖出1773.60万元，深股通为第一 大买入营业部及第一大卖出营业部，买入金额为2513.62万元，卖出金额为1868.99万元，合计净买入 644.63万元。 资金流向方面，今日该股主力资金净流出345.36万元，其中，特大单净流入287.59万元，大单资金净流 出632.94万元。近5日主力资金净流出205.18万元。（数据宝） 奥赛康5 ...

Core Viewpoint - The approval of Liratinib tablets for first-line treatment marks a significant breakthrough for the company in the field of targeted therapy for lung cancer, expanding its innovative drug strategy [1][2][8] Company Developments - The company’s subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for Liratinib tablets, which are indicated for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1][2] - Liratinib is a third-generation EGFR TKI developed collaboratively with the Chinese Academy of Sciences, featuring independent intellectual property rights and significant efficacy [1][2] Clinical Data and Efficacy - Clinical trials for Liratinib showed an objective response rate (ORR) of 68.8% and a disease control rate (DCR) of 92.4%, with a median duration of response (DoR) of 11.1 months and a median progression-free survival (PFS) of 11.0 months [4] - The drug demonstrated good efficacy in patients with central nervous system (CNS) metastases, with an ORR of 65.9% and a median PFS of 10.6 months [4] Market Potential and Commercialization - The domestic EGFR TKI market exceeds 20 billion yuan, and with the exclusive commercialization partnership with Innovent Biologics, Liratinib is expected to accelerate market penetration due to its efficacy and pricing advantages [5] - The company reported a net profit of 160 million yuan in 2024, indicating a turnaround and potential for stock price recovery and value reassessment [5] Research and Development Focus - The company has a robust pipeline with 42 ongoing projects, including 10 key innovative drugs in clinical research, and continues to invest heavily in R&D, with 354 million yuan allocated in 2024 [6][7] - The company aims to enhance its competitive edge by focusing on the development of small molecule targeted innovative drugs and tumor immunobiological innovative drugs [7][8]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

Regulatory Developments - The National Health Commission and other departments have released the 2025 National Random Supervision and Inspection Plan, which includes new regulatory areas such as internet diagnosis and treatment, and mental health, while explicitly targeting online medical fraud [1] - The regulatory focus on combating online medical fraud represents a significant upgrade in medical supervision, aiming to purify the medical online space [1] Pharmaceutical Approvals - Innovent Biologics announced that its third-generation EGFR TKI drug, Olitinib (Leratinib), has received approval from the National Medical Products Administration (NMPA) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [2] - Olitinib is the only approved third-generation EGFR TKI based on a naphthalene structure, expanding treatment options for EGFR mutation-positive NSCLC patients [2] Market Regulation and Antitrust Issues - Xianju Pharmaceutical is facing a potential fine of approximately 195 million yuan for alleged monopolistic practices related to the pricing of dexamethasone phosphate raw materials, with the case still under review by the Tianjin Market Supervision Administration [3] - This incident highlights the regulatory authorities' emphasis on antitrust measures within the pharmaceutical industry, which could disrupt normal market operations [3] Combination Therapy Approvals - Pfizer announced that its oral targeted drug, Axi-cabtagene ciloleucel (Axitinib), has been approved for first-line treatment in combination with Toripalimab for high-risk, unresectable, or metastatic renal cell carcinoma (RCC) patients [4] - This approval marks the first and only approved first-line targeted and immune combination therapy for advanced kidney cancer in China, indicating a shift towards combination therapies in the treatment landscape [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002755 证券简称：奥赛康 公告编号：2025-031 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □是 R否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 R否 （二） 非经常性损益项目和金额 R适用 □不适用 单位：元 其他符合非经常性损益定义的损益项目的具体情况 □适用 R不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 □适用 R不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第1号—— ...

北京奥赛康药业股份有限公司 1、个人基本情况 刘剑文，男，1959 年出生，中国国籍，无境外永久居留权。现任北京大学法 学院教授，博士生导师，中国法学会常务理事、中国法学会财税法学研究会会长。 1986 年 7 月至 1999 年 12 月，先后任武汉大学法学院讲师、副教授、教授、博 士生导师；1999 年 7 月至今任北京大学法学院教授、博士生导师。2018 年 5 月 至今任辽宁大学特聘教授。曾任公司第五届、第六届董事会独立董事。 2024 年度独立董事述职报告（刘剑文） 各位股东及股东代表： 本人作为北京奥赛康药业股份有限公司（以下简称"公司"）的独立董事，严 格依照《中华人民共和国公司法》（以下简称"公司法"）、《中华人民共和国 证券法》（以下简称"证券法"）、《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》以及其他有关法律法规和《公司章程》《公司独 立董事制度》的规定和要求，忠实勤勉地履行了独立董事的各项职责，谨慎认真 地行使了独立董事的权利，充分发挥了自身的专业优势，对公司董事会审议的相 关事项发表了独立客观的意见，切实维护了公司和广大股东特别是中小股东的合 法权益。现就 2 ...

北京奥赛康药业股份有限公司 2024 年度内部控制自我评价报告 北京奥赛康药业股份有限公司全体股东: 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合本公司（以下简称"公司"）内部控 制制度和评价办法，在内部控制日常监督和专项监督的基础上，我们对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全并有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立与实施内部控制进行监督。经理层负责组织领导公司内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证公司经营管理合法合规、资产安全、财务报 告及相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控 制存在固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变 化可能导致内部控制 ...

北京奥赛康药业股份有限公司（以下简称"公司"）2024 年财务决算工 作已完成，财务会计报告按照企业会计准则的规定编制，立信会计师事务 所（特殊普通合伙）出具了标准无保留意见的审计报告，现将有关财务决 算情况简要汇报如下： 北京奥赛康药业股份有限公司 2024 年度财务决算报告 一、主要会计数据： 经审计，立信会计师事务所（特殊普通合伙）出具了标准无保留意见的 审计报告，2024 年度公司实现营业收入 177,764.19 万元，较上年增加 23.15%。 归属于上市公司股东的净利润 16,029.43 万元，归属于上市公司股东扣除非 经常性损益后的净利润 12,623.95 万元，盈利分别较上年增加 207.92%、 155.50%。 单位：万元 项目 2024 年 2023 年 本年比上年 增减 2022 年 营业收入 177,764.19 144,345.96 23.15% 187,257.22 归属于上市公司股东的净利润 16,029.43 -14,852.98 207.92% -22,582.54 归属于上市公司股东的扣除非经 常性损益的净利润 12,623.95 -22,747.09 155.50 ...